Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies-Reference-Cited by-同舟云学术

Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies

Published:2015-11-20 Issue:1 Volume:103 Page:86-94
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Tobinai Kensei,Ogura Michinori,Ishizawa Kenichi,Suzuki Tatsuya,Munakata Wataru,Uchida Toshiki,Aoki Tomohiro,Morishita Takanobu,Ushijima Yoko,Takahara Satoko

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-015-1900-3.pdf

Reference20 articles.

1. Boffetta P. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011;22:iv27–iv31.

2. Ravandi F, O’Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2005;80:1660–74.

3. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000;50:696–702.

4. Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol. 1998;9:527–34.

5. Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2059–64.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma;International Journal of Hematology;2023-12-27

3. Pharmacokinetics of ibrutinib in a patient with chronic lymphocytic leukemia on hemodialysis;Clinical Nephrology;2022-12-01

4. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical;Drug Design, Development and Therapy;2022-09

5. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas;Cancers;2022-02-09